<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01740921</url>
  </required_header>
  <id_info>
    <org_study_id>066</org_study_id>
    <secondary_id>10/H0106/29</secondary_id>
    <nct_id>NCT01740921</nct_id>
  </id_info>
  <brief_title>GLP-1 and Microvascular Function in Type 2 Diabetes</brief_title>
  <acronym>GLP-1ADDS</acronym>
  <official_title>Does Glucagon-like Polypeptide 1 Improve Vascular Function and Inflammation?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Devon and Exeter NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Exeter</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Royal Devon and Exeter NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Some gut hormones, called incretins, stimulate insulin production in order to control sugar
      levels but also activate brain centres and signal to stop eating. Current administration of
      incretin-based therapies mimicking these gut hormones is by subcutaneous (just under the
      skin) injection and has been routinely available for diabetic patients for more than 4 years.
      It is an effective treatment for the lowering of blood glucose with an average weight loss of
      about 3-4kg.Recent evidence, from animal studies and limited human studies, suggests that
      incretins based treatments may also have beneficial effects on blood vessel function.
      However, it is not known whether this effect is by direct action on the blood vessel
      independent of an improvement of latent inflammation which is typically associated with
      weight loss or an anti-inflammatory effect of the incretin treatment itself. The aim of this
      study is to determine whether the incretin-based diabetes treatment with the GLP-1
      (Glucagon-like peptide 1) analogue Liraglutide (also known as Victoza), which mimics the
      actions of incretins, improves blood vessel function in individuals with type 2 diabetes. It
      will determine whether the improvement in blood vessel function is independent of the effect
      of weight loss and changes in inflammation. This by the study of vascular function before and
      after 4 months of Victoza treatment in subjects with Type 2 diabetes in comparison with 1)
      participants randomized to hypo-caloric diet to achieve a similar weight loss than with
      Victoza and 2) participants randomized to treatment with once daily aspirin. Comprehensive
      assessment of blood vessel function, body fat distribution and metabolic profile at baseline
      and at the end of the treatment phase will be combined with assessments of inflammation
      markers in blood and in fat tissue biopsies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change of baseline skin maximum hyperaemia at 4 months</measure>
    <time_frame>baseline and 4 months</time_frame>
    <description>laser doppler fluximetry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change of baseline peripheral arterial tone at 4 months</measure>
    <time_frame>baseline and 4 months</time_frame>
    <description>ITAMAR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of baseline endothelial-dependent vasodilation at 4 months</measure>
    <time_frame>baseline and 4 months</time_frame>
    <description>iontophoresis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of baseline capillary density at 4 months</measure>
    <time_frame>baseline and 4 months</time_frame>
    <description>capillaroscopy</description>
  </secondary_outcome>
  <other_outcome>
    <measure>change of baseline clot structure at 4 months</measure>
    <time_frame>baseline and 4 months</time_frame>
    <description>rigidity and elasticity of clot structure</description>
  </other_outcome>
  <other_outcome>
    <measure>change of baseline adipose tissue inflammation at 4 months</measure>
    <time_frame>baseline and 4 months</time_frame>
    <description>adipose tissue biopsies will be analysed for gene expression and protein content of inflammatory cytokines</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Liraglutide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Liraglutide (Victoza) daily injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>diet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>reduction in calorie intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Aspirin 300mg once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>Administered once daily</description>
    <arm_group_label>Liraglutide</arm_group_label>
    <other_name>Victoza</other_name>
    <other_name>GLP-1 analogue</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>diet</intervention_name>
    <description>reduction of caloric intake to promote weight loss</description>
    <arm_group_label>diet</arm_group_label>
    <other_name>caloric restriction</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>300mg of Aspirin per day</description>
    <arm_group_label>Aspirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes and an HbA1C between 7-8.5% on a stable dose of sulphonylurea and/or
             metformin

        Exclusion Criteria:

          -  use of insulin

          -  corticosteroids

          -  contraceptives, tamoxifen

          -  methotrexate

          -  DPP-IV inhibitors

          -  pregnancy

          -  lactation

          -  endocrine disorders

          -  acute MI or cerebrovascular disease

          -  Raynaud's disease or connective tissue disease

          -  current or previous history of malignancy

          -  subjects treated with ergotamine derivatives

          -  unstable blood pressure for the last 3 months

          -  current treatment with warfarin

          -  subjects on any anti-inflammatory or anti-platelet agents

          -  history of any bleeding disorders and GI bleeds.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katarina Kos, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Exeter</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peninsula Clinical Research Facility</name>
      <address>
        <city>Exeter</city>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Pastel E, McCulloch LJ, Ward R, Joshi S, Gooding KM, Shore AC, Kos K. GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction. Clin Sci (Lond). 2017 Mar 1;131(5):343-353. doi: 10.1042/CS20160803. Epub 2017 Jan 3.</citation>
    <PMID>28049736</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2012</study_first_submitted>
  <study_first_submitted_qc>December 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2012</study_first_posted>
  <last_update_submitted>February 16, 2017</last_update_submitted>
  <last_update_submitted_qc>February 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Royal Devon and Exeter NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Katarina Kos</investigator_full_name>
    <investigator_title>Senior Lecturer and Honorary Consultant Physician</investigator_title>
  </responsible_party>
  <keyword>GLP-1 analogues</keyword>
  <keyword>microvascular</keyword>
  <keyword>inflammation</keyword>
  <keyword>fat tissue</keyword>
  <keyword>clot structure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

